- Home
- SKM vs EXEL Comparison
SKM vs EXEL Comparison
Compare SKM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKM | EXEL |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 11.4B |
| IPO Year | 1999 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SKM | EXEL |
|---|---|---|
| Price | $38.04 | $43.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 21 |
| Target Price | N/A | ★ $46.45 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $4.51 | $13.61 |
| Revenue Next Year | $1.85 | $13.13 |
| P/E Ratio | $31.64 | ★ $16.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.66 | $33.76 |
| 52 Week High | $38.18 | $48.74 |
Technical Indicators
Market Signals| Indicator | SKM | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 75.20 | 49.78 |
| Support Level | $20.63 | $40.53 |
| Resistance Level | N/A | $44.32 |
| Average True Range (ATR) | 1.37 | 1.14 |
| MACD | 0.58 | 0.02 |
| Stochastic Oscillator | 82.04 | 30.48 |
Price Performance
Historical ComparisonAbout SKM SK Telecom Co. Ltd.
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.5 million pay TV customers (6.7 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.